Abstract：
Drugs that can treat one disease may either be detrimental or beneficial toward another due to possible cross-interactions. Therefore, care in choosing a suitable drug for patients with multiple diseases is crucial in successful patient management. This study explores several currently available ophthalmic drugs used to treat common ocular diseases to understand how they can affect the amyloidogenesis of a transforming growth factor β-induced protein (TGFBIp) peptide fragment found in abundance in the corneal protein aggregation deposits of lattice corneal dystrophy (LCD) patients. Results from this study provided supporting evidence that some drugs intended to treat other diseases can enhance or inhibit fibrillar aggregation of TGFBIp peptide, which may have potential implication of affecting the disease progression of LCD by either worsening or ameliorating it. Comparisons of the different properties of ophthalmic compounds explored in this study may also provide some guidance for future design of drugs geared toward the treatment of LCD.
摘要：
由于可能的交叉相互作用，可以治疗一种疾病的药物可能对另一种疾病有害或有益。因此,为多种疾病的患者选择合适的药物对成功的患者管理至关重要。这项研究探索了几种目前可用的用于治疗常见眼部疾病的眼科药物，以了解它们如何影响在晶格角膜蛋白聚集沉积物中大量发现的转化生长因子β诱导蛋白（TGFBIp）肽片段的淀粉样生成。角膜营养不良（LCD）患者。这项研究的结果提供了支持证据，表明一些旨在治疗其他疾病的药物可以增强或抑制TGFBIp肽的纤维聚集，这可能通过恶化或改善LCD而影响LCD的疾病进展。本研究中探索的眼用化合物的不同性质的比较也可能为将来设计用于治疗LCD的药物提供一些指导。
